ArticleBMC cancer2026

ERBITAG: Non-interventional study on the efficacy of cetuximab in first-line therapy in patients with RAS wild-type metastatic colorectal cancer.

Stephan W Sahm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.